TORONTO, Oct. 22, 2025 /CNW/ - Health Canada has approved Dupixent® (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) ...

First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark phase 3 studies showing Dupixent significantly reduced exacerbations, improved ...

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Sanofi logo at the company's headquarters during the annual results news conference in Paris (Reuters) -Sanofi won ...

Regeneron Pharmaceuticals , Sanofi SA announced an update on their ongoing clinical study. The Phase 1 study “Phase 1, Single Center, Open-label, Randomized, Parallel-group Stud ...

July 3 (Reuters) - Sanofi (SASY.PA), opens new tab and partner Regeneron (REGN.O), opens new tab on Wednesday won European Union approval for wider use of their Dupixent injection in patients with a ...

I, who want to live a slightly more peaceful daily life while recovering from asthma at home-Part 4 | Day 5 of Home ...

Dupixent (dupilumab), a drug already used to treat atopic dermatitis and asthma, became the first biologic approved for chronic obstructive pulmonary disease (COPD) last fall. Most COPD treatments ...

First biologic approved in the European Union for adults with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) Dupixent now approved in the EU for three type 2 inflammatory diseases: severe ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...